| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 84736 |
CAS: 870487-09-5， Boc-Val-Cit-PAB |
141 |
WYQ |
2024-12-19 |
| 84737 |
cas:2101206-67-9，Ald-Ph-amido-PEG1-C2-Pfp ester， ADC试剂 |
125 |
kx |
2024-12-19 |
| 84738 |
Ald-Ph-amido-PEG11-NH-Boc CAS:1245813-70-0 |
189 |
zyl |
2024-12-19 |
| 84739 |
HSA-2-iminothiolane-DOTA HSA-2-亚氨基硫醇-DOTA |
146 |
h |
2024-12-19 |
| 84740 |
cas:1222787-24-7，2,5-Dioxopyrrolidin-1-yl 4-((2-((2-(2-(4-(2,6-dioxo-1,3-dipropyl-2,3,6,9-tetrahydro-1H-purin-8-yl)phenoxy)acetamido)ethyl)amino)ethyl)disulfanyl)-4-oxobutanoate |
260 |
kx |
2024-12-19 |
| 84741 |
Tr-PEG5-OH CAS:141282-24-8物理化学性质 |
178 |
zyl |
2024-12-19 |
| 84742 |
CAS: 870487-08-4，Boc-Val-Cit，(S)-2-((S)-2-((叔丁氧基羰基)氨基)-3-甲基丁酰胺基)-5-脲基戊酸 |
144 |
WYQ |
2024-12-19 |
| 84743 |
DOTA-8-Aoc-BBN[7-14]NH |
176 |
h |
2024-12-19 |
| 84744 |
Fmoc-PEG3-Val-Cit，N-Fluorenylmethoxycarbonyl-triethylene glycol-Val-Cit |
157 |
WYQ |
2024-12-19 |
| 84745 |
CAS: 2226472-28-0，DBCO-PEG4-Val-Cit-PAB-PNP |
123 |
WYQ |
2024-12-19 |
| 84746 |
CAS: 2055024-64-9，Azido-PEG4-Val-Cit-PAB-OH |
151 |
WYQ |
2024-12-19 |
| 84747 |
CAS: 870487-09-5，Boc-Val-Cit-PAB |
151 |
WYQ |
2024-12-19 |
| 84748 |
CAS:784105-33-5 Amino-PEG3-C2-acid的介绍 |
130 |
zyl |
2024-12-19 |
| 84749 |
CAS 863971-53-3：Fmoc-Val-Cit-PAB-PNP |
133 |
WYQ |
2024-12-19 |
| 84750 |
Ald-Ph-amido-PEG11-C2-NH2 CAS:1337889-01-6 |
129 |
zyl |
2024-12-19 |
| 84751 |
cas:2003260-13-5 ， MA-PEG4-Ala-Ala-PAB-PNP，ADC定制 |
147 |
wyh |
2024-12-19 |
| 84752 |
DOTA-NCS-6-Ahx-Phe 19-ST[1-19] DOTA偶联ST肽类似物 |
167 |
h |
2024-12-19 |
| 84753 |
1,4,7,10-四氮杂-n-(1-羧基-3-(4-硝基苯基)丙基)-n,N , N ‴-tris(acetic酸)环十二烷(PA-DOTA) |
122 |
h |
2024-12-19 |
| 84754 |
CAS 159858-22-7：Fmoc-Val-Cit-PAB-OH |
134 |
WYQ |
2024-12-19 |
| 84755 |
cas:5117-19-1，Octanethyl glycol ，八乙二醇的主要特点 |
231 |
zyl |
2024-12-19 |
| 84756 |
CAS 159857-79-1：Val-Cit-PAB-OH，缬氨酸（Val）、琥珀酰亚胺（Cit）和对氨基苯甲酸（PAB）的衍生物 |
171 |
WYQ |
2024-12-19 |
| 84757 |
SPDP-Val-Cit-PAB-OH，ADC定制 |
130 |
wyh |
2024-12-19 |
| 84758 |
DOTA-LVT 螯合剂DOTA偶联Lys8-血管收缩素 |
215 |
h |
2024-12-19 |
| 84759 |
cas:2054345-67-2，azido-tris(ethylenoxy)-L-alanine TFA Salt化学性质 |
145 |
zyl |
2024-12-19 |
| 84760 |
cas:68617-64-1，SPDP acid，3-(2-吡啶二硫代)丙酸的合成方法 |
207 |
zyl |
2024-12-19 |
| 84761 |
1,4,7,10-四(羧甲基)-1,4,7,10-四氮杂环十二烷单酰胺偶联葡萄糖 |
165 |
h |
2024-12-19 |
| 84762 |
PEG-P(Asp-Gd-DOTA)Gd‐DOTA偶联聚乙二醇改性聚天冬氨酸 |
169 |
h |
2024-12-19 |
| 84763 |
cas:70539-42-3，EGS Crosslinker，乙二醇-双(琥珀酸N-羟基琥珀酰亚胺酯)的结构式 |
351 |
zyl |
2024-12-19 |
| 84764 |
CXCR4导向的五肽[(68)Ga]喷替沙福(环(-D-Tyr-N-Me-D-Orn(AMB-DOTA)-L-Arg-L-2-Nal-Gly-)) |
213 |
h |
2024-12-19 |
| 84765 |
α-hexadecyl-DOTA α-十六烷基-DOTA |
164 |
h |
2024-12-19 |
| 84766 |
Methyltetrazine-SS-NHS 甲基四唑-双硫键-活性酯的合成方法 |
156 |
zyl |
2024-12-19 |
| 84767 |
DOTA-AgRP-6E |
192 |
h |
2024-12-19 |
| 84768 |
DOTA-morab-003 DOTA偶联单克隆抗体MORAb-003 |
179 |
h |
2024-12-19 |
| 84769 |
DOTA-Bz-folate DOTA-Bz-叶酸 |
162 |
h |
2024-12-19 |
| 84770 |
cas:55750-53-3，6-Maleimidocaproic acid，6-马来酰亚氨基己酸 |
207 |
zyl |
2024-12-19 |
| 84771 |
cas: Fmoc-PEG3-Val-Cit，ADC定制 |
187 |
wyh |
2024-12-19 |
| 84772 |
钆(III)DOTA-DSPE脂质体 |
165 |
h |
2024-12-19 |
| 84773 |
CAS: 870487-08-4，Boc-Val-Cit，叔丁氧羰基-缬氨酰-L-瓜氨酸 |
130 |
WYQ |
2024-12-19 |
| 84774 |
DOTA-Phe-D-Trp-Lys-Thr-OMe DOTA偶联生长抑素四肽类似物 |
200 |
h |
2024-12-19 |
| 84775 |
CAS: 35665-38-4，Fmoc-Gly-Gly-OH，Fmoc-甘氨酰-甘氨酸 |
192 |
WYQ |
2024-12-19 |
| 84776 |
cas:117235-10-6，3-Mercaptopropanyl-N-hydroxysuccinimide ester的结构式 |
178 |
zyl |
2024-12-19 |
| 84777 |
DOTA-PEG(4)-BBN(7-14)-AuNP DOTA-神经介素n功能化NHS活化的PEG-金纳米颗粒 |
158 |
h |
2024-12-19 |
| 84778 |
cas:2226472-28-0，DBCO-PEG4-Val-Cit-PAB-PNP，ADC定制 |
124 |
wyh |
2024-12-19 |
| 84779 |
CAS: 863971-53-3，Fmoc-Val-Cit-PAB-PNP |
143 |
WYQ |
2024-12-19 |
| 84780 |
tris-苄基-DOTA tris-benzyl-DOTA |
176 |
h |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询